Results 71 to 80 of about 825,078 (353)

Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review

Frontiers in Pharmacology
In light of the expected increase in the prevalence of diabetes mellitus due to an aging population, sedentary lifestyles, an increase in obesity, and unhealthy diets, there is a need to identify potential pharmacological agents that can heighten the ...
Takudzwa Mugiya, Mamosheledi Mothibe, Andile Khathi, Phikelelani Ngubane, Ntethelelo Sibiya   +4 more
doaj   +1 more source

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

Haematologica, 2013
Response to tyrosine kinase inhibitors at three months is a predictor for long-term outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Aziz Nazha, Hagop Kantarjian, Preetesh Jain, Carlos Romo, Elias Jabbour, Alfonso Quintas-Cardama, Raja Luthra, Lynne Abruzzo, Gautam Borthakur, Farhad Ravandi, Sherry Pierce, Susan O’Brien, Jorge Cortes   +12 more
doaj   +1 more source

Gene amplifications associated with the development of hormone- resistant prostate cancer [PDF]

, 2003
Purpose: Hormone resistance remains a significant clinical problem in prostate cancer with few therapeutic options. Research into mechanisms of hormone resistance is essential.
Bartlett, J.M.S., Edwards, J., Krishnan, S., Witton, C.J.   +3 more
core  

Essential Role of Lyn in Fibrosis. [PDF]

, 2016
Fibrotic disorders involve replacement of normal parenchyma with myofibroblasts, which deposit connective tissue, leading to obliteration of the function of the underlying organ.
Birtolo, Chiara, Chheda, Chintan, Cirulli, Vincenzo, Gugliotta, Gabriele, Lewis, Michael S, Liu, Sandy T, Pandol, Stephen J, Pham, Hung, Ptasznik, Andrzej, Rodriguez, Maria D, Yang, Wendy   +10 more
core   +2 more sources

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later

Revista de Investigación Clínica
Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias.
Max Robles-Nasta, Daniela Sánchez-Bonilla, Moises M. Gallardo-Pérez, Edgar J. Hernández-Flores, Merittzel A. Montes-Robles, María de L. Pastelín-Martínez, Juan C. Olivares-Gazca, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles   +8 more
doaj   +1 more source

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

Haematologica, 2013
There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as third-line alternative ...
Antonella Russo Rossi, Massimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, Luigiana Luciano, Antonella Gozzini, Mario Annunziata, Bruno Martino, Fabio Stagno, Francesco Cavazzini, Mario Tiribelli, Giuseppe Visani, Patrizia Pregno, Pellegrino Musto, Carmen Fava, Nicola Sgherza, Francesco Albano, Gianantonio Rosti, Giuliana Alimena, Giorgina Specchia   +19 more
doaj   +1 more source

Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo [PDF]

, 2007
Endothelial cell survival is indispensable to maintain endothelial integrity and initiate new vessel formation. We investigated the role of SHP-2 in endothelial cell survival and angiogenesis in vitro as well as in vivo.
Alavi A, Barbara Walzog, Bennett AM, Brooks PC, Chan RJ, Chang F, Chen J, Christian Plank, Crompton T, Cunnick JM, Distler JH, Florian Krötz, Frisch SM, Hadari YR, Hae-Young Sohn, Hanna Mannell, Hu Y, Huang P, Ivins Zito C, Kontaridis MI, Krotz F, Krotz F, Krotz F, Krotz F, Leopold Groesser, Munoz-Chapuli R, Neel BG, Neel BG, Nicole Hellwig, Noguchi T, Nor JE, Ong SH, O’Brien CD, Papetti M, Plank C, Qi JH, Qi JH, Qu CK, Ren Y, Saxton TM, Shi ZQ, Slater EP, Tang TL, Thakker GD, Tomanek RJ, Torsten Gloe, Ulrich Pohl, Wu CJ, Yart A, Zhang SQ, Zhang SQ   +50 more
core   +1 more source

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases [PDF]

Breast Cancer Research, 2000
ERBB family receptor tyrosine kinases are overexpressed in a significant subset of breast cancers. One of these receptors, HER2/neu, or ErbB-2, is the target for a new rational therapeutic antibody, Herceptin. Other inhibitors that target this receptor, and another family member, the epidermal growth factor (EGF) receptor, are moving into clinical ...
openaire   +2 more sources

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source